Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ENSC vs BFRI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENSC Captures Overall Composite Edge (53.4 HOLD vs 44.0 HOLD), While BFRI Leads 3–1 on Growth & Valuation Pillars

ENSC Overall Winner 6-Pillar Tally: ENSC 1 – 3 BFRI (2 Tie) Matrix Metrics: ENSC 5 – 4 BFRI

As of Nov 20, 2026, Ensysce Biosciences, Inc. (ENSC) captures the overall head-to-head institutional edge over Biofrontera Inc. (BFRI) on higher Unified Composite conviction (53.4/100 HOLD vs. 44.0/100 HOLD) after splitting the core matrix 5–4 (led by Valuation Multiples), while BFRI wins 3–1 across the 6-pillar growth and valuation breakdown. ENSC trades at $0.36 (0.8x Forward P/E, -281.3% operating margin) versus BFRI at $0.53 (13.0x Forward P/E, -12.6% operating margin).

  • Growth vs. Quality Trade-Off: ENSC earns the overall head-to-head edge with a stronger Unified Composite Score (53.4/100 HOLD vs. BFRI 44.0/100 HOLD) and 0.98β · 79% Vol risk profile, whereas BFRI leads top-line expansion (+29.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ENSC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7); meanwhile BFRI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENSC vs BFRI
ENSC NASDAQ Head-to-Head Winner
Ensysce Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$0.36
-0.17% 1D
Market Cap $7.0M
TTM Revenue $4.5M
Forward P/E 0.8x
Beta / 30D Vol 0.98β · 79% Vol
Unified Composite Score
53.4 / 100 HOLD
Tech 50.0 Fund 62.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.4%), weak momentum, RSI 40
RSI-14: 39.7 · SMA20: $0.39 · SMA50: $0.44
BFRI NASDAQ
Biofrontera Inc. Common Stock
Pharmaceutical Preparations
$0.53
-7.02% 1D
Market Cap $10.2M
TTM Revenue $48M
Forward P/E 13.0x
Beta / 30D Vol 1.84β · 125% Vol
Unified Composite Score
44.0 / 100 HOLD
Tech 25.0 Fund 42.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.2%), weak momentum, RSI 28
RSI-14: 27.5 · SMA20: $0.79 · SMA50: $0.93

6-Pillar Scorecard Institutional Category Breakdown (ENSC 1 – 3 BFRI)

Columns: Metric · ENSC · BFRI
1. Valuation Multiples ENSC
Forward P/E 0.8x 13.0x
Trailing P/E 0.8x 13.0x
PEG Ratio N/M N/M
EV / Revenue 1.4x 0.2x
2. Growth & Scale BFRI
Revenue Growth (YoY) -15.1% +29.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $4.5M $48M
Market Cap $7.0M $10.2M
3. Profitability & Quality BFRI
Gross Margin N/A 79.6%
Operating Margin -281.3% -12.6%
Net Profit Margin -280.5% -12.7%
Return on Equity (ROE) -1295.1% -988.4%
4. Balance Sheet & Cash Flow BFRI
Cash Generation (TTM) -$9.7M -$9.3M
Cash Flow Margin N/A -19.3%
Net Cash / Leverage -$499,633 Net Debt $1.4M Net Debt (1.27x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENSC (5) vs BFRI (4)
Institutional Metric ENSC BFRI Criterion Row Edge
Market Capitalization
Scale
$7.0M $10.2M Larger Scale Tie
Trailing P/E Ratio
Valuation
0.8x 13.0x Lower Multiple ENSC
Forward P/E Ratio
Valuation
0.8x 13.0x Lower Multiple ENSC
Revenue Growth (YoY)
Growth
-15.1% +29.8% Higher Growth BFRI
Operating Margin (TTM)
Profitability
-281.3% -12.6% Higher Margin BFRI
Net Profit Margin
Profitability
-280.5% -12.7% Higher Margin BFRI
Return on Equity (ROE)
Capital Efficiency
-1295.1% -988.4% Higher ROE BFRI
52-Week Range Position
Momentum
8% ($0–$2) 0% ($1–$2) Stronger Trend ENSC
Beta / 30D Volatility
Risk Regime
0.98β · 79% Vol 1.84β · 125% Vol Lower Realized Risk ENSC
Unified Institutional Score
Composite Signal
53.4 / 100 (HOLD) 44.0 / 100 (HOLD) Higher Composite ENSC
Trailing 12M Revenue (USD)
Operating Scale
$4.5M $48M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 79.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.4x EV/Rev N/M PEG · 0.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.7M (-$499,633 Net Debt) -$9.3M ($1.4M Net Debt (1.27x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENSC +2.59 pp
ENSC: -29.55% · BFRI: -32.14%
3M Horizon ENSC +63.42 pp
ENSC: -0.28% · BFRI: -63.7%
6M Horizon ENSC +47.34 pp
ENSC: +12.99% · BFRI: -34.35%
1Y Horizon BFRI +45.84 pp
ENSC: -80.33% · BFRI: -34.49%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ENSC Revenue BFRI Revenue ENSC Op. Margin BFRI Op. Margin Margin Leader
FY2020 $0M $20M -41.0% -51.0% ENSC
FY2021 $0M $20M -562.7% -104.6% BFRI
FY2022 $0M $30M -959.9% -64.8% BFRI
FY2023 $0M $30M -480.5% -66.6% BFRI
FY2024 $10M $40M -129.2% -46.1% BFRI
FY2025 $10M $40M -202.1% -27.2% BFRI

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENSC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ENSC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BFRI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BFRI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENSC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.0M market capitalization and -281.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BFRI Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $10.2M market capitalization and -12.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENSC vs BFRI Key Questions & Quantitative Answers

As of Nov 20, 2026, Ensysce Biosciences, Inc. (ENSC) captures the overall head-to-head institutional edge over Biofrontera Inc. (BFRI) on higher Unified Composite conviction (53.4/100 HOLD vs. 44.0/100 HOLD) after splitting the core matrix 5–4 (led by Valuation Multiples), while BFRI wins 3–1 across the 6-pillar growth and valuation breakdown. ENSC trades at $0.36 (0.8x Forward P/E, -281.3% operating margin) versus BFRI at $0.53 (13.0x Forward P/E, -12.6% operating margin). Growth vs. Quality Trade-Off: ENSC earns the overall head-to-head edge with a stronger Unified Composite Score (53.4/100 HOLD vs. BFRI 44.0/100 HOLD) and 0.98β · 79% Vol risk profile, whereas BFRI leads top-line expansion (+29.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ENSC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7); meanwhile BFRI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BFRI leads the Growth & Scale pillar: ENSC posts -15.1% YoY revenue growth and +0.0% YoY earnings growth on $4.5M TTM revenue (N/A gross margin, -281.3% operating margin), compared with BFRI at +29.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (79.6% gross margin, -12.6% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), ENSC cumulative revenue shifted +0.0% while BFRI shifted +100.0%. In operating R&D and SG&A reinvestment, ENSC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BFRI.

ENSC screens cheaper on headline valuation multiples. ENSC trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (unreported FCF margin), whereas BFRI trades at 13.0x Forward P/E, 13.0x Trailing P/E, N/M PEG, and 0.2x EV/Revenue (-19.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENSC (-1295.1% ROE) versus BFRI (-988.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ENSC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 79% Vol realized risk). By comparison, BFRI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.84β · 125% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.